Home > Insider Trading > Filing (0001209191-19-017835)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1662524	Akcea Therapeutics Inc.	AKCA	Pharmaceutical Preparations (2834)	472608175

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1692444	Paula Soteropoulos	C/O Akcea Therapeutics, Inc. 22 Boston Wharf Road, 9Th Floor Boston MA 02210	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-03-06	18,386	$6.48	18,386	No	4	M	Direct
Common Stock	Disposition	2019-03-06	18,386	$32.14	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2019-03-06	18,386	$0.00	18,386	$6.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,742,866		2025-12-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The weighted average sale price for the transaction reported was $32.1362, and the range of prices were between $32.11 and $32.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years.